ADC
Antibody-Drug Conjugates: Connecting Drugs to Cancer Cells and Unlocking Billions in Market Opportunities
2024-11-06
DualityBio, Partner of BioNTech and BeiGene, Files for Hong Kong IPO, Highlighting Several Potential First-in-Class ADCs
2024-08-29
ROR1 in Focus as a target for ADC-based treatments: Recent Developments and Industry Challenges – Part III
2024-08-07
BIO Asia-Taiwan 2024 Conference has Officially Started, With International Leaders in the Industry Gathering Despite the Storm
2024-07-25